A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

1. Ojea, A.
2. Nogueira, J.L.
3. Solsona, E.
4. Flores, N.
5. Gómez, J.M.F.
6. Molina, J.R.
7. Chantada, V.
8. Camacho, J.E.
9. Piñeiro, L.M.
10. Rodríguez, R.H.
11. Isorna, S.
12. Blas, M.
13. Martínez-Piñeiro, J.A.
14. Madero, R.